Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Active, not recruiting Observational

The Kunshan Elderly Health Study

NCT05141565 · tracked via the Priya Life Science China tracker
Phase
Observational
Started
2021-05-17
Last updated
2024-04-22

Condition(s) studied

Cardiovascular DiseasesDiabetes MellitusCancerCognitive ImpairmentSarcopeniaFrailtyDepression

Investigational drug(s) / intervention(s)

No intervention

No intervention: No intervention

Study summary

The Kunshan Elderly Health Study (KEHS) is a community-based prospective cohort study of chronic disease, mortality and associated factors among elderly adults in Kunshan, Eastern China.

Eligibility

Sex
ALL
Min age
65 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Locally registered-residents in Kunshan * Aged 65 years or above * Voluntary agreement to participate in the study (with written informed consent) Exclusion Criteria: * Patients with stroke, coronary heart disease or cancer * Patients with severe physical or mental illness * People unable to complete the survey

Primary outcome measure(s)

  • Incidence of chronic diseases — Trough study completion, an average of 10 years
    Chronic diseases including cardiovascular disease, diabetes, cancer, etc. will be identified by chronic disease registries and active follow-up
  • Mortality — Trough study completion, an average of 10 years
    Total and cause-specific mortality

Trial sites (1)

FacilityCityRegionStatus
Kunshan Center for Disease Control and Prevention Kunshan Jiangsu
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05141565 on ClinicalTrials.gov ↗ ← All trials in China